Menu Search
Equities

hVIVO PLC

CRO:DUS

hVIVO PLC

Actions
  • Price (EUR)0.26
  • Today's Change0.008 / 3.17%
  • Shares traded10.10k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It operates through medical and scientific research services segment. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 11+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services. It offers additional clinical field trial services, such as Challenge Models, Pre-clinical, CMC & PK, Study Design & Protocol Development, Ethics & Regulatory, Phase I & II, Volunteer/Patient Recruitment, Clinical site, Monitoring, Biometrics, and Medical Writing. Its subsidiaries include hVIVO Holdings Limited, Open Orphan DAC, hVIVO Inc., and others.

  • Revenue in GBP (TTM)64.38m
  • Net income in GBP17.45m
  • Incorporated2011
  • Employees274.00
  • Location
    hVIVO PLC42 New RoadLONDON E1 2AXUnited KingdomGBR
  • Phone+44 289 073 7900
  • Websitehttps://hvivo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.